Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

Return to program book search

Session Information

SYM S040 - Cutaneous Oncology

Open admission to eligible categories, no tuition or ticket


Date: Monday, March 04

CME Credits: 3.00

Location: Room C220/221/222

Time: 9:00 AM - 12:00 PM

Director: Darrell S. Rigel, MD, FAAD - Handout


  • Roger I. Ceilley, MD, FAAD - Handout
  • Clay J. Cockerell, MD, FAAD - Handout
  • Laura K. Ferris, MD, PhD, FAAD
  • Robert J. Friedman, MD
  • Sancy A. Leachman, MD, PhD, FAAD
  • Mark Lebwohl, MD, FAAD - Handout
  • Theodore Rosen, MD, FAAD
  • Abel Torres, MD, JD, FAAD - Handout
  • Steven Q. Wang, MD, FAAD
  • Martin A. Weinstock, MD, PhD, FAAD

Learning Objectives:
Following this course, the attendee should be able to:

  • Identify and better respond to the typical issues that arise in skin cancer management
  • Provide the best patient care to patients with skin cancer
  • Best assess the risk factors and prognosis for skin cancer

The most important management issue that we face on a daily basis in dermatology from a life-and-death perspective is skin cancer. In the past decade, dermatologists have evolved from merely diagnosing skin cancer to being actively involved in all phases of management. It is therefore incumbent upon us to be up to date on all aspects of cutaneous oncology. The goal of this symposium is to provide the most up-to-date information on melanoma to the practicing dermatologist so that our responses to the issues that we deal with in skin cancer on a daily basis can be optimized.


  • Cancer of the Skin. Rigel et al eds. Elsevier Publishing, 2011.


Monday, March 04
9:00 AMIntroduction and review of today's session / Dr. Rigel
9:05 AMWhich Makes More Sense for Treating AKS – Field or Lesional Therapy? / Dr. Rosen
9:20 AMDoes Sunscreen Usage Lower the Risk for Skin Cancer? / Dr. Ceilley
9:35 AMDo Sunscreen Ingredients Put the User at Risk? / Dr. Wang
9:50 AMDo Psoriasis Therapies put Patients at Increased Risk for Skin Cancer? / Dr. Lebwohl
10:05 AMShould the Management of Dysplastic Nevi be Focused on Precursor or Marker Implications? / Dr. Cockerell
10:20 AMQ and A / Dr. Rigel, Dr. Ceilley, Dr. Rosen, Dr. Wang, Dr. Lebwohl, and Dr. Cockerell
10:35 AMDo Devices have a significant impact on Melanoma Diagnosis? / Dr. Ferris
10:50 AMMelanoma Prevention Strategies – Should we focus on Primary or Secondary Prevention strategies? / Dr. Weinstock
11:05 AMIs it Time for Genetic Testing in Melanoma – Why When and Who? / Dr. Leachman
11:20 AMHow Effective are the Newer Medical Therapies for Advanced Skin Cancer? / Torres
11:35 AMDoes Sentinel Node Biopsy Impact Melanoma Survival in Melanoma Patients? / Dr. Friedman
11:50 AMQ and A / Dr. Friedman, Dr. Ferris, Dr. Swetter, Dr. Leachman, and Torres